P2RX6

P2RX6 encodes an ATP-gated cation channel subunit of the P2X family characterized by two predicted transmembrane segments and a large extracellular loop, with slow desensitization and an atypical pharmacology insensitive to alpha,beta-methylene-ATP, suramin, and PPADS in its initial recombinant form (PMID:8786426). Unlike other P2X subunits, P2X6 fails to oligomerize into stable homomeric channels when expressed alone: chemical cross-linking yields no higher-order adducts and AFM shows a monomer-sized molecular volume (PMID:15657042). This failure is imposed by an uncharged 14-amino-acid N-terminal region that blocks assembly and ER export, retaining the subunit as an ER monomer; charging or deleting this region permits homotrimer formation and surface trafficking, though such homotrimers remain non-functional (PMID:16452399). P2X6 acquires function by co-assembling into heteromeric receptors with P2X4 (P2X4/6), P2X2 (P2X2/6), or both as a P2X2/4/6 heterotrimer, each displaying pharmacology distinct from the parent homomers (PMID:9736638, PMID:10864944, PMID:24815693). Functional surface expression is further gated by N-linked glycosylation, with the additionally glycosylated ~70 kDa species conferring agonist sensitivity (PMID:15044628). Beyond its channel role, P2X6 undergoes age-dependent nuclear accumulation in hippocampal neurons, where it is retained by spectrin alpha2 and interacts with splicing factor SF3A1 to reduce mRNA splicing activity (PMID:25874565). The gene is transcriptionally induced by p53 and predominantly expressed in skeletal muscle (PMID:9242461), and ATP-driven P2RX6 signaling promotes renal cell carcinoma migration via a Ca2+-pERK1/2-MMP9 cascade controlled by METTL14-dependent m6A modification of its mRNA (PMID:31159832).

1. 1996 High

   Established that P2X6 is an ATP-gated cation channel with a distinct pharmacology, while its low expression hinted it does not normally function as a homomultimer.

   Evidence cDNA cloning and heterologous expression in Xenopus oocytes with electrophysiology and pharmacology

   PMID:8786426

   Open questions at the time

   • Did not resolve subunit stoichiometry or whether homomeric channels form at all
   • No native tissue function established
2. 1997 Medium

   Linked P2X6 transcription to p53 and localized its expression to skeletal muscle, framing it as a p53-responsive gene.

   Evidence p53-binding site cloning, Northern blot, and RT-PCR in sarcoma cell lines

   PMID:9242461

   Open questions at the time

   • p53-driven transcription not confirmed by reporter or mutagenesis assay
   • Functional consequence of the M1-lacking splice variant not tested
3. 1998 High

   Showed P2X6 gains function through heteromerization, co-assembling with P2X4 to form a receptor with novel pharmacology, answering how a weak homomer becomes physiologically relevant.

   Evidence Xenopus oocyte co-expression electrophysiology and epitope-tagged co-purification from HEK-293 cells

   PMID:9736638

   Open questions at the time

   • Subunit stoichiometry of the P2X4/6 heteromer not defined
   • Native co-assembly in endogenous tissue not demonstrated
4. 2000 High

   Extended the heteromer repertoire by showing P2X6 partners with P2X2 to produce a channel with altered agonist potency and pH modulation.

   Evidence Xenopus oocyte co-expression and two-electrode voltage-clamp pharmacology

   PMID:10864944

   Open questions at the time

   • Single-lab characterization
   • Physiological context of P2X2/6 receptors not established
5. 2002 Medium

   Placed P2X6 at endothelial cell-cell junctions but distinguished it from P2X4 by its inability to bind VE-cadherin, clarifying partner specificity.

   Evidence Confocal/electron microscopy, co-immunoprecipitation, and Triton extraction in HUVECs

   PMID:12088286

   Open questions at the time

   • P2X6 junctional localization itself is lower-tier microscopy evidence
   • Functional role at junctions not defined
6. 2004 High

   Identified N-linked glycosylation as a post-translational switch determining whether surface P2X6 is functional, explaining variability in recombinant channel activity.

   Evidence Whole-cell patch-clamp, Western blot, N-glycosidase F treatment, and surface biotinylation

   PMID:15044628

   Open questions at the time

   • Glycosylation sites not mapped
   • Whether glycosylation regulates native heteromers not addressed
7. 2005 High

   Demonstrated directly that P2X6 cannot form stable homomers, settling whether the subunit oligomerizes alone.

   Evidence Chemical cross-linking and atomic force microscopy with antibody decoration

   PMID:15657042

   Open questions at the time

   • Did not identify the structural determinant blocking oligomerization
   • Heteromer assembly geometry not addressed
8. 2005 Low

   Suggested an inflammatory modulation of P2X6, where TNFalpha prevents agonist-induced mRNA downregulation and may sustain ATP-driven apoptosis in cardiac fibroblasts.

   Evidence Primary cardiac fibroblast culture, qRT-PCR, and apoptosis assay with TNFalpha treatment

   PMID:16242142

   Open questions at the time

   • mRNA-level measurement does not confirm a P2X6-specific channel mechanism
   • Apoptosis not causally linked to P2X6 activity
9. 2006 High

   Pinpointed the uncharged 14-residue N-terminal region as the molecular cause of ER retention, mechanistically explaining why P2X6 requires a partner subunit to traffic.

   Evidence Site-directed mutagenesis of the N-terminus with immunocytochemistry, surface biotinylation, and AFM

   PMID:16452399

   Open questions at the time

   • Why N-terminal mutant homotrimers remain non-functional unresolved
   • ER retention machinery recognizing this region not identified
10. 2007 Low

    Reported developmental alternative splicing of P2X6 transcripts in neuronal differentiation and brain maturation.

    Evidence RT-PCR in P19 cells and mouse brain at multiple time points

    PMID:17259301

    Open questions at the time

    • No functional validation of the spliced form's channel properties
    • RT-PCR only, no protein-level confirmation
11. 2014 High

    Established that all three subunits can co-assemble into a single P2X2/4/6 heterotrimer, defining the most complex P2X6-containing receptor.

    Evidence Sequential co-immunoprecipitation and AFM with dual antibody decoration in tsA201 cells

    PMID:24815693

    Open questions at the time

    • Functional properties of the P2X2/4/6 trimer not characterized
    • Native existence of this trimer not shown
12. 2015 Medium

    Revealed a non-canonical nuclear role for P2X6, where age-dependent nuclear accumulation and interaction with SF3A1 reduce mRNA splicing, decoupling the subunit from channel function.

    Evidence Immunofluorescence in hippocampal neurons, co-immunoprecipitation of spectrin alpha2 and SF3A1, and in vivo splicing activity assay

    PMID:25874565

    Open questions at the time

    • Single-lab finding without independent replication
    • Mechanism translating ER anchorage into nuclear entry not detailed
    • Physiological significance of reduced splicing not established
13. 2019 Medium

    Connected P2RX6 to cancer cell behavior, showing ATP-P2RX6-Ca2+ signaling drives renal carcinoma invasion under METTL14/m6A translational control.

    Evidence Migration/invasion assays, Ca2+ imaging, Western blot for pERK1/2 and MMP9, xenografts, and m6A analysis with METTL14 manipulation

    PMID:31159832

    Open questions at the time

    • m6A-P2RX6 link relies on expression-level data
    • Whether P2RX6 acts as a homomer or heteromer in this context not resolved

• The functional properties and native physiological roles of the heteromeric P2X6 receptors, and the in vivo significance of its nuclear splicing-regulatory function, remain unresolved.
• No high-resolution structure of any P2X6-containing channel
• Endogenous tissue expression of specific heteromers undefined
• Causal disease role not established by genetic evidence